Last reviewed · How we verify
trastuzumab (H)
trastuzumab (H) is a HER2-targeted monoclonal antibody Small molecule drug developed by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. It is currently FDA-approved for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (adjuvant therapy), HER2-positive metastatic gastric cancer. Also known as: qutuozhudankang.
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.
Trastuzumab is used to treat various stages of breast cancer, including Stage IIIA, Stage IIIB, and Stage IV, as well as Inflammatory Breast Cancer. It is often administered in combination with other treatments such as doxorubicin hydrochloride and cyclophosphamide.
At a glance
| Generic name | trastuzumab (H) |
|---|---|
| Also known as | qutuozhudankang |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | HER2-targeted monoclonal antibody |
| Target | HER2 (human epidermal growth factor receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Trastuzumab targets human epidermal growth factor receptor 2 (HER2), a protein overexpressed in certain cancers. By binding to HER2, it prevents ligand-induced signaling and recruits immune cells to destroy HER2-positive tumor cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Approved indications
- HER2-positive metastatic breast cancer
- HER2-positive early-stage breast cancer (adjuvant therapy)
- HER2-positive metastatic gastric cancer
Common side effects
- Cardiotoxicity / left ventricular dysfunction
- Infusion reactions
- Diarrhea
- Nausea
- Fatigue
- Headache
- Fever
Key clinical trials
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (PHASE2)
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread (PHASE1, PHASE2)
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer (PHASE2)
- Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma (PHASE1, PHASE2)
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) (PHASE2)
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- trastuzumab (H) CI brief — competitive landscape report
- trastuzumab (H) updates RSS · CI watch RSS
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University portfolio CI
Frequently asked questions about trastuzumab (H)
What is trastuzumab (H)?
How does trastuzumab (H) work?
What is trastuzumab (H) used for?
Who makes trastuzumab (H)?
Is trastuzumab (H) also known as anything else?
What drug class is trastuzumab (H) in?
What development phase is trastuzumab (H) in?
What are the side effects of trastuzumab (H)?
What does trastuzumab (H) target?
Related
- Drug class: All HER2-targeted monoclonal antibody drugs
- Target: All drugs targeting HER2 (human epidermal growth factor receptor 2)
- Manufacturer: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for HER2-positive metastatic breast cancer
- Indication: Drugs for HER2-positive early-stage breast cancer (adjuvant therapy)
- Indication: Drugs for HER2-positive metastatic gastric cancer
- Also known as: qutuozhudankang
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing